MediciNova, Inc. — FY2011 Form 10-K Summary
Business context and reporting period
MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing small-molecule therapeutics for serious diseases with unmet medical needs. The filing covers the fiscal year ended December 31, 2011, with quarterly data for the fourth quarter ended December 31, 2011. The company had no approved products or commercial product sales and relied on external manufacturers, contract research organizations and potential strategic partners.
Resources were concentrated on MN-221 for acute asthma and COPD exacerbations and MN-166, an ibudilast-based program for progressive multiple sclerosis and other central nervous system disorders. Eight other programs were substantially deprioritized, with development generally limited to maintaining license rights or preserving potential value.
Key financial metrics
| Metric | FY2011 | FY2010 | Change |
|---|---|---|---|
| Revenue | $0 | $0 | No change |
| Research and development expense | $7.8 million | $9.7 million | Down $1.9 million |
| General and administrative expense | $8.3 million | $8.2 million | Up $0.1 million |
| Total operating expenses | $16.1 million | $17.9 million | Down $1.8 million |
| Operating loss | $16.1 million | $17.9 million | Improved $1.8 million |
| Net loss | $17.7 million | $20.2 million | Improved $2.5 million |
| Basic and diluted loss per share | $1.20 | $1.63 | Improved $0.43 |
| Net cash used in operating activities | $13.3 million | $17.7 million | Improved $4.4 million |
| Cash and cash equivalents at year-end | $15.1 million | $28.3 million | Down $13.2 million |
| Working capital | $12.0 million | $21.6 million | Down $9.5 million |
Operating and net margins are not meaningful because the company generated no revenue. Accumulated deficit reached $285.3 million at December 31, 2011. Total assets were $30.8 million and stockholders’ equity was $23.5 million.
The company had no debt at year-end. It repaid its $15.0 million Oxford Finance loan in April 2011 and repaid the remaining Avigen-related convertible notes at maturity in June 2011, except for approximately $76,000 converted into 11,246 common shares. Interest expense remained $1.6 million in 2011, primarily reflecting debt-related charges and repayment accounting.
Fourth-quarter 2011 operating expenses were $3.5 million and net loss was $3.5 million, or $0.22 per share, compared with fourth-quarter 2010 operating expenses of $4.3 million and net loss of $5.0 million, or $0.40 per share.
Material changes versus the prior comparable period
- R&D expense declined primarily because MN-221 spending fell by approximately $1.6 million and unallocated R&D costs declined following headcount reductions.
- General and administrative expense was broadly stable; higher severance, consulting and legal costs offset lower compensation and stock-based compensation costs.
- Cash declined by $13.2 million, principally because operating cash use exceeded financing proceeds after debt repayment.
- MediciNova raised approximately $7.7 million net from a March 2011 public offering of common stock and warrants and approximately $7.5 million gross from Kissei’s October 2011 purchase of common and convertible preferred stock.
- Kissei also paid a $2.5 million nonrefundable upfront amount for MN-221 research and development services. The amount was recorded as deferred revenue; no revenue was recognized in 2011.
- The company entered into a China joint venture agreement with Zhejiang Medicine and Beijing Make-Friend Medicine to develop and commercialize MN-221. A required Kissei-consented sublicense had not been executed as of the filing date.
- The company reduced its workforce in January 2011 and had 14 full-time employees as of March 27, 2012.
Guidance, outlook, commentary and risks
Management stated that cash and working capital at December 31, 2011 were expected to fund operating requirements through at least December 31, 2012. This assessment assumes no MN-221 Phase 3 trial and no significant additional MN-166 development unless the company raises capital or obtains a strategic collaboration. Management expects continued substantial operating losses and stated that additional financing will be required to complete development and commercialization activities.
Enrollment in the 176-patient Phase 2 MN-221-CL-007 asthma trial was completed in March 2012, with results expected in the second quarter of 2012. Subject to acceptable results and additional financing or partnering, MediciNova intended to define and initiate a Phase 3 program. A new Phase 1b/2a COPD trial began in the first quarter of 2012, with anticipated completion around the end of the second quarter of 2012.
MN-166 development beyond limited ongoing studies was largely contingent on a strategic collaboration or funding arrangement. The company was pursuing partners for progressive MS, neuropathic pain, addiction indications and other programs, but gave no assurance that collaborations would be obtained on acceptable terms or at all.
- Clinical, regulatory and commercial failure could prevent any product from reaching approval or generating revenue.
- Available cash may be insufficient for pivotal trials, commercialization or expanded development, creating financing and dilution risk.
- The company depends heavily on MN-221 and MN-166, licensors, third-party manufacturers, CROs and strategic partners.
- Future potential license milestone payments totaled approximately $94.1 million, excluding royalties; timing and occurrence were uncertain.
- Patent protection is uneven. MN-166 lacks composition-of-matter patent protection, and certain patents covering MN-001 and MN-305 had expired.
- The China joint venture may not obtain the required sublicense, funding, regulatory approvals or commercial success.
- A former employee lawsuit had been compelled to arbitration; management did not expect a material adverse outcome.
- Auditors issued unqualified opinions on the financial statements and internal control over financial reporting. Management reported effective disclosure controls and internal controls as of December 31, 2011.
Important facts for investors to verify
- Final results of the MN-221-CL-007 Phase 2 asthma trial and whether the FDA supports a Phase 3 path.
- Cash burn, financing needs and the actual duration of the $15.1 million year-end cash balance.
- Terms and execution of the MN-221 China sublicense and the performance of the joint venture.
- Potential dilution from 3.1 million outstanding options, warrants and other equity awards, plus 220,000 Series B preferred shares convertible into 2.2 million common shares.
- Status of strategic partnering efforts for MN-166 and the other non-prioritized programs.
- Unfunded license milestones, royalty obligations and third-party clinical and manufacturing commitments.
- Patent duration, enforceability and freedom-to-operate for MN-221 and MN-166.
- Whether the $2.5 million Kissei deferred revenue will be recognized as services are performed and whether related costs materially affect future cash burn.